Vimarsana
Biggest News Aggregation in the World

Featured Research Session News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Featured Research Session. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Featured Research Session Today - Breaking & Trending Today

Acumen Pharmaceuticals, Inc. Presents Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease at the Alzheimer’s Association International Conference 2023 - Vimarsana News

Acumen Pharmaceuticals, Inc. Presents Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease at the Alzheimer’s Association International Conference 2023

Published: July 17, 2023

Acumen Pharmaceuticals, Inc.  presented positive topline results from the Phase 1 INTERCEPT-AD trial of ACU193, the first clinical-stage AßO targeting antibody therapy in early AD, at the...

Source: marketscreener.com
Related Topics:
Noord HollandAcumen Pharmaceuticals IncAssociation International ConferenceResearch SessionAcumen PharmaceuticalsStatistically Significant Amyloid PlaqueWell Tolerated Across Dose CohortsConsistent Dose Related PharmacokineticsDose Related Target EngagementFeatured Research Session
Acumen Pharmaceuticals Presents Positive Topline Results - Vimarsana News

Acumen Pharmaceuticals Presents Positive Topline Results

Published: July 16, 2023

Topline results from INTERCEPT-AD trial met primary and secondary objectives, demonstrating proof-of-mechanism for ACU193, the first clinical-stage amyloid...

Source: globenewswire.com
Related Topics:
Noord HollandNew YorkUnited StatesAlex BraunLawrence HonigDaniel OconnellSteven DekoskyJessica LaubEric SiemersUniversity Of FloridaMcknight Brain InstituteYork State CenterAlzheimer Association International ConferenceExchange CommissionAlzheimer Disease At Columbia UniversityResearch SessionAcumen Pharmaceuticals IncAcumen PharmaceuticalsDrug AdministrationAssociation International ConferenceDanielo ConnellChief Executive OfficerAmyloid PlaqueWell Tolerated Across DoseConsistent Dose Related Pharmacokinetics
Amprion's αSynuclein Seed Amplification Assay to be Showcased at Alzheimer's Association International Conference® 2023 (AAIC®) - Vimarsana News

Amprion's αSynuclein Seed Amplification Assay to be Showcased at Alzheimer's Association International Conference® 2023 (AAIC®)

Published: July 15, 2023

/PRNewswire/ -- Amprion, a global leader in the advancement of neurodegenerative disorder diagnosis, will be in attendance at the Alzheimer's Association...

Source: prnewswire.com
Related Topics:
United StatesLuis ConchaRussell LebovitzDouglas GalaskoFrancesca CapotostiDoug GalaskoLawren VandevredePrnewswire AmprionOskar HanssonClaudio SotoEthan MetelenisAmprion Syntap BiomarkerChristina RenfroeAmprion SyntapUniversity Of California San DiegoAlzheimer Association International ConferenceUniversity Of California San FranciscoLaboratory Developed TestWeill Institute For NeurosciencesA Featured Research SessionDrug AdministrationUniversity Of Texas Health Sciences Center HoustonAssociation InternationalLewy Body DementiaLewy Body
Acumen Pharmaceuticals to Present Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer's Disease During Featured Research Session at the Alzheimer's Association International Conference (AAIC®) 2023 - Vimarsana News

Acumen Pharmaceuticals to Present Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer's Disease During Featured Research Session at the Alzheimer's Association International Conference (AAIC®) 2023

Published: June 13, 2023

Topline results for ACU193, the first clinical stage amyloid beta oligomer -directed antibody, to provide deeper insight into candidate’s therapeutic potential for the treatment of early... | June 13, 2023

Source: marketscreener.com
Related Topics:
Noord HollandNew YorkUnited StatesKimball JohnsonSteven DekoskyEric SiemersDaniel OconnellLawrence HonigDrug AdministrationResearch SavannahAcumen Pharmaceuticals IncResearch SessionAlzheimer Disease At Columbia UniversityAlzheimer Association International ConferenceExchange CommissionMcknight Brain InstituteResearch AtlantaYork State CenterUniversity Of FloridaFeatured Research SessionDeveloping TopicsAssociation International ConferenceDanielo ConnellChief Executive OfficerChief Medical Officer